The purpose of this study, a single-center, open, single-dose clinical study, was to evaluate the safety, tolerability, and pharmacokinetic profile of IM83 CAR-T cells in the treatment of patients with relapsed or refractory osteosarcoma
Age ≥ 16 years, both male and female;
Subjects with a diagnosis of osteosarcoma of the extremity confirmed by pathohistologic examination;
To enroll subjects with recurrent or refractory extremity osteosarcoma who have failed or are intolerant to first-line standard therapy and who are not candidates for radical surgery and/or localized therapy and who lack effective subsequent treatment.
Standard treatment failure was defined as disease relapse or progression during or within 6 months of completion of treatment with first-line chemotherapeutic agents (including high-dose methotrexate, doxorubicin, cisplatin, isocyclophosphamide, etc.);
Presence of brain metastases;
Subjects who have previously received or are awaiting an organ transplant;
Toxicity due to prior therapy not stabilized or recovered to ≤ grade 1 (except in cases judged by the investigator to be not clinically significant);
Autoimmune diseases requiring systemic immunosuppressive therapy, such as systemic lupus erythematosus, rheumatoid arthritis, and ulcerative colitis, within 2 years prior to the start of screening;
Map coordinates are unavailable for these locations. Locations are shown below instead.
ChinaBeijing Immunochina Medical Science & Technology Co., Ltd.
Lead sponsor
Guangdong Provincial People's Hospital
Collaborator